Replies to post #780 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Has this study been part of a wider clinical program for a new application or does the existing approval of ATiii-applications in Europe allow for these kind of experiments?<

This was a single-center study with plasma-derived antithrombin. It was not part of a clinical program involving ATryn. Of course, any setting where plasma-derived AT works, ATryn should work too.